Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03640481
Other study ID # DRI17633
Secondary ID KD025-213U1111-1
Status Terminated
Phase Phase 2
First received
Last updated
Start date October 11, 2018
Est. completion date December 11, 2023

Study information

Verified date December 2023
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of systemic therapy


Description:

Phase 2, open label, randomized, multicenter study in subjects with cGVHD who have previously been treated with at least 2 prior lines of systemic therapy. Approximately 166 subjects with active cGVHD will be randomized (1:1) to receive treatment with one of two belumosudil (formerly known as KD025) regimens: - Arm A: belumosudil 200 mg QD - Arm B: belumosudil 200 mg BID With Amendment 2, the sample size was increased from approximately 126 subjects, with additional subjects to be enrolled as follows: - 20 adolescents - 20 adults into a site-specific Companion Study to collect biospecimens These additional subjects will also be randomized (1:1) to Arm A or Arm B. Any adolescent taking a proton pump inhibitor (PPI) or a strong CYP3A4 inducer will begin Cycle 1 Day 1 at the escalated dose of belumosudil 200 mg BID. Randomization will be stratified according to prior cGVHD treatment with ibrutinib (Yes / No) and severe cGVHD at baseline (Yes / No). Subjects may receive treatment in 28-day treatment cycles until clinically significant progression of cGVHD. Subjects who have not achieved a response after 12 cycles of belumosudil should be withdrawn if in the Investigator's judgment there is no evidence of clinical benefit. Subjects will undergo evaluations as outlined in the Study Assessments table (Appendix A). The primary endpoint is the overall response rate (ORR) with responses as defined by the 2014 National Institute of Health (NIH) Consensus Development Project on clinical trials in cGVHD.


Recruitment information / eligibility

Status Terminated
Enrollment 159
Est. completion date December 11, 2023
Est. primary completion date December 11, 2023
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: 1. Male and female subjects at least 12 years of age who have had allogenic hematopoietic cell transplant (HCT). 2. Previously received at least 2 and not more than 5 lines of systemic therapy for cGVHD 3. Receiving glucocorticoid therapy with a stable dose over the 2 weeks prior to screening 4. Have persistent cGVHD manifestations and systemic therapy is indicated 5. Karnofsky Performance Score of = 60 (if aged 16 years or older); Lansky Performance Score of = 60 (if aged < 16 years) 6. Weight = 40kg Exclusion Criteria: 1. Subjects has not been on a stable dose / regimen of systemic cGVHD treatments for at least 2 weeks prior to screening. (Note: Concomitant corticosteroids, calcineurin inhibitors, sirolimus, MMF, methotrexate, rituximab, and extracorporeal photophoresis (ECP) are acceptable. Systemic investigational GVHD treatments are not permitted). 2. Histological relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening. 3. Current treatment with ibrutinib. Prior treatment with ibrutinib is allowed with a washout of at least 28 days prior to randomization.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Belumosudil (KD025)
Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

Locations

Country Name City State
United States CS Mott Children's Hospital Site Number : 157 Ann Arbor Michigan
United States Emory University School of Medicine Site Number : 100 Atlanta Georgia
United States Augusta University Medical Center Site Number : 093 Augusta Georgia
United States South Austin Medical Center Site Number : 091 Austin Texas
United States Center for Cancer Research National Cancer Institute Site Number : 107 Bethesda Maryland
United States University of Alabama at Birmingham (UAB) - Children's of Alabama Site Number : 156 Birmingham Alabama
United States Dana-Farber Cancer Institute Site Number : 004 Boston Massachusetts
United States Massachusetts General Hospital Site Number : 002 Boston Massachusetts
United States University of Illinois at Chicago Site Number : 139 Chicago Illinois
United States The Cleveland Clinic Foundation Site Number : 041 Cleveland Ohio
United States James Cancer Hospital & Wexner Medical Center at the Ohio State University Comprehensive Cancer Center Site Number : 103 Columbus Ohio
United States University of Texas Southwestern Site Number : 155 Dallas Texas
United States Colorado Blood Cancer Institute Site Number : 098 Denver Colorado
United States Barbara Ann Karmanos Cancer Institute-4100 John R St Site Number : 094 Detroit Michigan
United States Childrens Hospital of Michigan Site Number : 161 Detroit Michigan
United States City of Hope Medical Center Site Number : 050 Duarte California
United States University of Kansas Cancer Center Site Number : 105 Fairway Kansas
United States MD Anderson Cancer Center Site Number : 057 Houston Texas
United States University of Iowa Site Number : 126 Iowa City Iowa
United States University of California, Los Angeles (UCLA) - Medical Center Site Number : 104 Los Angeles California
United States University of Wisconsin - Carbone Cancer Center Site Number : 135 Madison Wisconsin
United States University of Miami - Sylvester Cancer Center Site Number : 097 Miami Florida
United States Froedtert Hospital and the Medical College of Wisconsin Site Number : 101 Milwaukee Wisconsin
United States University of Minnesota Site Number : 051 Minneapolis Minnesota
United States Sarah Cannon and HCA Research Institute Site Number : 007 Nashville Tennessee
United States Vanderbilt University Medical Center Site Number : 063 Nashville Tennessee
United States Childrens Hospital of Orange County Site Number : 165 Orange California
United States Phoenix Childrens Hospital Site Number : 154 Phoenix Arizona
United States University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center Site Number : 132 Pittsburgh Pennsylvania
United States Oregon Health & Science University (OHSU) Site Number : 095 Portland Oregon
United States University of Rochester Site Number : 106 Rochester New York
United States Washington University School of Medicine Site Number : 125 Saint Louis Missouri
United States Texas Transplant Institute Site Number : 079 San Antonio Texas
United States University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center Site Number : 058 San Francisco California
United States Fred Hutchinson Cancer Research Center Site Number : 052 Seattle Washington
United States Stanford Cancer Center Site Number : 108 Stanford California
United States Moffitt Site Number : 102 Tampa Florida
United States University of Arizona - Cancer Center Site Number : 122 Tucson Arizona
United States Wake Forest Site Number : 123 Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Kadmon, a Sanofi Company

Country where clinical trial is conducted

United States, 

References & Publications (1)

Przepiorka D, Le RQ, Ionan A, Li RJ, Wang YH, Gudi R, Mitra S, Vallejo J, Okusanya OO, Ma L, Yang Y, Patel P, Mezaache D, Shah R, Banerjee A, McLamore S, Maung AN, Goldberg KB, Pazdur R, Theoret MR, De Claro RA. FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy. Clin Cancer Res. 2022 Jun 13;28(12):2488-2492. doi: 10.1158/1078-0432.CCR-21-4176. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Response Rate (ORR) The primary endpoint is the ORR with responses as defined by the 2014 National Institute of Health (NIH) Consensus Development Project on clinical trials in cGVHD. up to approximately 40 months
Secondary Duration of Response (DOR) The time from initial response of PR or CR until documented progression of cGVHD up to approximately 40 months
Secondary Change in Lee Symptom Scale Score Analyses will include: Number of subjects with a =7 point reduction, Number of subjects with a =7 point reduction on 2 consecutive assessments and Duration of a =7 point reduction. Symptom burden will be assessed on Day 1 of each cycle starting on Cycle 1 Day 1, as well as at the EOT visit. The questionnaire asks subjects to indicate the degree of bother that they experienced due to symptoms in seven domains potentially affected by chronic GVHD (skin, eyes, mouth, breathing, eating and digestion, energy, and emotional distress). The response will be determined based on clinician assessment specifically for each of affected organ as a Complete Response, Partial Response or Progression. up to approximately 40 months
Secondary Response rate by organ system The response assessment for the nine individual organs (Skin, Eyes, Mouth, Esophagus, Upper GI, Lower GI, Liver, Lungs, and Joints and fascia). up to approximately 40 months
Secondary Percentage of subjects who have a best response of PR or CR up to approximately 40 months
Secondary Change in corticosteroid dose up to approximately 40 months
Secondary Change in calcineurin inhibitor dose up to approximately 40 months
Secondary Failure-free survival (FFS) FFS is defined as the absence of cGVHD treatment change, non-relapse mortality and recurrent malignancy. Median FFS (from first dose of belumosudil) and landmark FFS at 1 year will be analyzed. up to approximately 7 years
Secondary Overall Survival (OS) Time from first dose of belumosudil to the date of death due to any cause. up to approximately 7 years
Secondary Change in cGVHD severity as based on the Physician-reported global cGVHD Activity Assessment Physician-reported outcome up to approximately 40 months
Secondary Change in symptom activity as based on cGVHD Activity Assessment Patient Self-Report Patient-reported outcome up to approximately 40 months
Secondary Determine the Peak Plasma Concentration (Cmax) of belumosudil Determine the maximum plasma concentration (Cmax) of belumosudil Pre-dose and post-dose sampling within 12 hours
Secondary Determine the observed time to reach peak plasma concentration (Tmax) of belumosudil The time that belumosudil reach the maximum plasma concentration (Tmax). Pre-dose and post-dose sampling within 12 hours
Secondary Determine the half-life (T1/2) of belumosudil The time it takes for half of belumosudil to be removed from plasma by biological processes (T1/2) Pre-dose and post-dose sampling within 12 hours
Secondary Determine the area under the plasma concentration versus time curve (AUC) of belumosudil Area under the plasma concentration versus time curve (AUC) Pre-dose and post-dose sampling within 12 hours
Secondary Time to Response The time it takes to obtain a cGVHD response to belumosudil. up to approximately 40 months
Secondary Time to next treatment The time it takes to initiate a new systemic cGVHD treatment after starting belumosudil. up to approximately 40 months
Secondary Number pf participants with adverse event and serious adverse events Safety will be assessed by monitoring adverse events, clinical laboratory evaluations, vital sign measurements, and ECG parameters. Up to 28 days after the last dose of study treatment i.e., up to approximately 7 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04189432 - Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease Phase 2
Terminated NCT03557749 - Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
Completed NCT05121142 - Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease Phase 1
Recruiting NCT04202835 - ATG Plus PTCy vs ATG for CGVHD Prophylaxis Phase 2
Completed NCT01036958 - Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease
Recruiting NCT04372524 - Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
Active, not recruiting NCT03604692 - A Phase 1/2 Study to Evaluate SNDX- 6352 in Participants With Active cGVHD Phase 1/Phase 2
Recruiting NCT05355675 - The Association of Microbiota Composition With cGVHD After Allo-HSCT
Active, not recruiting NCT04710576 - A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) Phase 2
Terminated NCT04200365 - A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) Phase 2
Not yet recruiting NCT06263478 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease Phase 3
Not yet recruiting NCT06388564 - A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease Phase 2
Terminated NCT02123966 - An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease Phase 2
Recruiting NCT05692713 - Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)
Terminated NCT04446182 - Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD Phase 2
Active, not recruiting NCT05305989 - Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213 Phase 2
Active, not recruiting NCT02340676 - A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD Phase 2
Completed NCT04540133 - Dexamethasone Solution and Dexamethasone in Mucolox™ Phase 2
Not yet recruiting NCT03190733 - A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT Phase 4
Active, not recruiting NCT04716075 - Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) Phase 2